These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 38445519)

  • 1. Tertiary Lymphoid Structure-Associated B Cells Enhance CXCL13
    Hu C; You W; Kong D; Huang Y; Lu J; Zhao M; Jin Y; Peng R; Hua D; Kuang DM; Chen Y
    Gastroenterology; 2024 Jun; 166(6):1069-1084. PubMed ID: 38445519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer.
    Mori T; Tanaka H; Suzuki S; Deguchi S; Yamakoshi Y; Yoshii M; Miki Y; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
    Cancer Sci; 2021 May; 112(5):1746-1757. PubMed ID: 33735485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional Heterogeneity of CD4
    Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
    Front Immunol; 2018; 9():2654. PubMed ID: 30505306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD103
    Corgnac S; Malenica I; Mezquita L; Auclin E; Voilin E; Kacher J; Halse H; Grynszpan L; Signolle N; Dayris T; Leclerc M; Droin N; de Montpréville V; Mercier O; Validire P; Scoazec JY; Massard C; Chouaib S; Planchard D; Adam J; Besse B; Mami-Chouaib F
    Cell Rep Med; 2020 Oct; 1(7):100127. PubMed ID: 33205076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Emerging Role of CD8
    Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
    Front Immunol; 2018; 9():1904. PubMed ID: 30158938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatty Acid Oxidation Controls CD8
    Lin R; Zhang H; Yuan Y; He Q; Zhou J; Li S; Sun Y; Li DY; Qiu HB; Wang W; Zhuang Z; Chen B; Huang Y; Liu C; Wang Y; Cai S; Ke Z; He W
    Cancer Immunol Res; 2020 Apr; 8(4):479-492. PubMed ID: 32075801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of CD103
    Han L; Gao QL; Zhou XM; Shi C; Chen GY; Song YP; Yao YJ; Zhao YM; Wen XY; Liu SL; Qi YM; Gao YF
    Cancer Immunol Immunother; 2020 Aug; 69(8):1493-1504. PubMed ID: 32285170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Transcriptionally Distinct CXCL13
    Workel HH; Lubbers JM; Arnold R; Prins TM; van der Vlies P; de Lange K; Bosse T; van Gool IC; Eggink FA; Wouters MCA; Komdeur FL; van der Slikke EC; Creutzberg CL; Kol A; Plat A; Glaire M; Church DN; Nijman HW; de Bruyn M
    Cancer Immunol Res; 2019 May; 7(5):784-796. PubMed ID: 30872264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR6 deficiency impairs cancer vaccine efficacy and CD8
    Karaki S; Blanc C; Tran T; Galy-Fauroux I; Mougel A; Dransart E; Anson M; Tanchot C; Paolini L; Gruel N; Gibault L; Lepimpec-Barhes F; Fabre E; Benhamouda N; Badoual C; Damotte D; Donnadieu E; Kobold S; Mami-Chouaib F; Golub R; Johannes L; Tartour E
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-resident memory CD103+CD8+ T cells in colorectal cancer: its implication as a prognostic and predictive liver metastasis biomarker.
    Liu S; Wang P; Wang P; Zhao Z; Zhang X; Pan Y; Pan J
    Cancer Immunol Immunother; 2024 Jul; 73(9):176. PubMed ID: 38954030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution, phenotype, functional and clinical relevance of CD8
    Shen Y; Li XL; Li YX; Shan ZG; Zhao YL; Cheng P; Zhao Z; Zhang JY; Chen W; Zhuang Y; Ma DY; Zou QM; Qiu Y; Peng LS
    Cancer Immunol Immunother; 2022 Jul; 71(7):1645-1654. PubMed ID: 34767045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
    Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paxillin Binding to the Cytoplasmic Domain of CD103 Promotes Cell Adhesion and Effector Functions for CD8
    Gauthier L; Corgnac S; Boutet M; Gros G; Validire P; Bismuth G; Mami-Chouaib F
    Cancer Res; 2017 Dec; 77(24):7072-7082. PubMed ID: 29021139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactive glia promote development of CD103
    Prasad S; Hu S; Sheng WS; Chauhan P; Lokensgard JR
    Immun Inflamm Dis; 2018 Jun; 6(2):332-344. PubMed ID: 29602245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-resident memory CD8
    Wang T; Shen Y; Luyten S; Yang Y; Jiang X
    Pharmacol Res; 2020 Sep; 159():104876. PubMed ID: 32422340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD103
    Edwards J; Wilmott JS; Madore J; Gide TN; Quek C; Tasker A; Ferguson A; Chen J; Hewavisenti R; Hersey P; Gebhardt T; Weninger W; Britton WJ; Saw RPM; Thompson JF; Menzies AM; Long GV; Scolyer RA; Palendira U
    Clin Cancer Res; 2018 Jul; 24(13):3036-3045. PubMed ID: 29599411
    [No Abstract]   [Full Text] [Related]  

  • 18. Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade.
    Banchereau R; Chitre AS; Scherl A; Wu TD; Patil NS; de Almeida P; Kadel Iii EE; Madireddi S; Au-Yeung A; Takahashi C; Chen YJ; Modrusan Z; McBride J; Nersesian R; El-Gabry EA; Robida MD; Hung JC; Kowanetz M; Zou W; McCleland M; Caplazi P; Eshgi ST; Koeppen H; Hegde PS; Mellman I; Mathews WR; Powles T; Mariathasan S; Grogan J; O'Gorman WE
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
    Cabrita R; Lauss M; Sanna A; Donia M; Skaarup Larsen M; Mitra S; Johansson I; Phung B; Harbst K; Vallon-Christersson J; van Schoiack A; Lövgren K; Warren S; Jirström K; Olsson H; Pietras K; Ingvar C; Isaksson K; Schadendorf D; Schmidt H; Bastholt L; Carneiro A; Wargo JA; Svane IM; Jönsson G
    Nature; 2020 Jan; 577(7791):561-565. PubMed ID: 31942071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
    Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
    Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.